Lufeng Zhao

581 total citations
22 papers, 412 citations indexed

About

Lufeng Zhao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Lufeng Zhao has authored 22 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 4 papers in Immunology. Recurrent topics in Lufeng Zhao's work include Lung Cancer Diagnosis and Treatment (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Immune Cell Function and Interaction (3 papers). Lufeng Zhao is often cited by papers focused on Lung Cancer Diagnosis and Treatment (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Immune Cell Function and Interaction (3 papers). Lufeng Zhao collaborates with scholars based in China. Lufeng Zhao's co-authors include Pin Wu, Lijian Huang, Dang Wu, Ying Chai, Jian Huang, Gang Shen, Zhigang Zhang, Gang Shen, Gang Chen and Jiwei Cheng and has published in prestigious journals such as Journal of Clinical Oncology, Frontiers in Immunology and European Journal of Immunology.

In The Last Decade

Lufeng Zhao

20 papers receiving 409 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lufeng Zhao China	9	199	162	117	114	109	22	412
Lijian Huang China	8	177 0.9×	151 0.9×	98 0.8×	80 0.7×	113 1.0×	20	388
Chengjuan Zhang China	15	174 0.9×	239 1.5×	63 0.5×	123 1.1×	121 1.1×	39	477
Suguru Hayase Japan	16	193 1.0×	282 1.7×	76 0.6×	109 1.0×	97 0.9×	34	511
Olfat Al‐Harazi Saudi Arabia	10	335 1.7×	229 1.4×	155 1.3×	88 0.8×	120 1.1×	14	578
Yi‐Fang Tsai Taiwan	13	173 0.9×	219 1.4×	42 0.4×	94 0.8×	123 1.1×	47	473
Baoen Shan China	15	173 0.9×	296 1.8×	67 0.6×	66 0.6×	158 1.4×	46	516
Angela Poehlmann Germany	12	165 0.8×	295 1.8×	61 0.5×	82 0.7×	99 0.9×	13	526
Jingmei Su China	8	187 0.9×	239 1.5×	67 0.6×	52 0.5×	83 0.8×	11	402
Ramón González Manzano Spain	10	176 0.9×	334 2.1×	56 0.5×	82 0.7×	86 0.8×	21	491
Yuzhou Zhao China	11	242 1.2×	207 1.3×	146 1.2×	132 1.2×	158 1.4×	33	544

Countries citing papers authored by Lufeng Zhao

Since Specialization

Citations

This map shows the geographic impact of Lufeng Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lufeng Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lufeng Zhao more than expected).

Fields of papers citing papers by Lufeng Zhao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lufeng Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lufeng Zhao. The network helps show where Lufeng Zhao may publish in the future.

Co-authorship network of co-authors of Lufeng Zhao

This figure shows the co-authorship network connecting the top 25 collaborators of Lufeng Zhao. A scholar is included among the top collaborators of Lufeng Zhao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lufeng Zhao. Lufeng Zhao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huang, Yü, et al.. (2024). Efficacy of befotertinib in non-small cell lung cancer harboring uncommon compound EGFR mutations G719X and S768I: a case report. Frontiers in Oncology. 14. 1370666–1370666. 2 indexed citations

Yao, Jie, Lufeng Zhao, Lili Li, et al.. (2024). NeoSCORE II: Three Vs Four Cycles of Neoadjuvant Sintilimab + Chemotherapy for Squamous Non-Small-Cell Lung Cancer. Future Oncology. 20(3). 121–129.

Chen, Xiaoke, Di Chen, Lufeng Zhao, et al.. (2022). Tissue‐resident CD69 ⁺ CXCR6 ⁺ Natural Killer cells with exhausted phenotype accumulate in human non‐small cell lung cancer. European Journal of Immunology. 52(12). 1993–2005. 11 indexed citations

Qiu, Fuming, Junqiang Fan, Jie Yao, et al.. (2022). Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial.. Journal of Clinical Oncology. 40(16_suppl). 8500–8500. 30 indexed citations

Yao, Jie, et al.. (2021). ZNF655 is involved in development and progression of non-small-cell lung cancer. Life Sciences. 280. 119727–119727. 8 indexed citations

Wu, Pin, Lufeng Zhao, Xiaoke Chen, et al.. (2021). CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer. Cancer Immunology Immunotherapy. 70(12). 3603–3616. 16 indexed citations

Gu, Haihua, Tianshu Liu, Ling Zhu, Lufeng Zhao, & Junqiang Fan. (2021). A multidisciplinary collaborative model based on single-port thoracoscopy for the treatment of giant mediastinal lymph node hyperplasia: a case report. Journal of International Medical Research. 49(12). 3619123708–3619123708.

Huang, Lijian, Lufeng Zhao, Shijie Wang, et al.. (2020). CD8+ T Cells Form the Predominant Subset of NKG2A+ Cells in Human Lung Cancer. Frontiers in Immunology. 10. 3002–3002. 32 indexed citations

Zhao, Lufeng, et al.. (2019). Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cells. Medical Oncology. 36(11). 91–91. 21 indexed citations

10.

Huang, Lijian, Pin Wu, Lufeng Zhao, & Ying Chai. (2018). Reduced complexity of uniportal video-assisted thoracoscopic left upper sleeve lobectomy. Journal of Thoracic Disease. 10(6). 3791–3796. 2 indexed citations

11.

Chai, Ying, Y. Wu, & Lufeng Zhao. (2018). Pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymph tissue: A case report and literature review. Nigerian Journal of Clinical Practice. 21(3). 392–392. 5 indexed citations

12.

Huang, Lijian, et al.. (2018). Demonstrating suspending the pulmonary artery. ASVIDE. 5. 578–578. 1 indexed citations

13.

Huang, Lijian, Pin Wu, Lufeng Zhao, & Ying Chai. (2018). Demonstrating a double-embedding stitching method and the process of pulling out the chest tube. ASVIDE. 5. 580–580. 1 indexed citations

14.

Huang, Lijian, Wenshan Li, Lufeng Zhao, Baizhou Li, & Ying Chai. (2017). Risk factors of lymph node metastasis in lung squamous cell carcinoma of 3 cm or less in diameter. Medicine. 96(29). e7563–e7563. 7 indexed citations

15.

Wu, Pin, Dang Wu, Lufeng Zhao, et al.. (2016). Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis. Oncotarget. 7(15). 19863–19883. 121 indexed citations

16.

Wu, Pin, Dang Wu, Lufeng Zhao, et al.. (2016). Inverse role of distinct subsets and distribution of macrophage in lung cancer prognosis: a meta-analysis. Oncotarget. 7(26). 40451–40460. 64 indexed citations

17.

Huang, Lijian, et al.. (2016). Left bronchial isomerism in a lung cancer patient undergoing right upper pulmonary lobectomy via a thoracoscope. Thoracic Cancer. 8(1). 54–56. 2 indexed citations

18.

Wu, Dang, Pin Wu, Lufeng Zhao, et al.. (2015). NF-κB Expression and Outcomes in Solid Tumors. Medicine. 94(40). e1687–e1687. 81 indexed citations

19.

Zhang, Guofei, et al.. (2015). Pulmonary resection and systemic lymph node dissection in a patient with breast cancer who had a 33-year disease-free interval. World Journal of Surgical Oncology. 13(1). 150–150. 2 indexed citations

20.

Wu, Dang, et al.. (2015). NF-κB Expression and Outcomes in Solid Tumors. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact